{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T08:06:03Z","timestamp":1770969963616,"version":"3.50.1"},"reference-count":24,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2011,12,27]],"date-time":"2011-12-27T00:00:00Z","timestamp":1324944000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2012,4]]},"abstract":"<jats:p>\n                    <jats:bold>Aims:<\/jats:bold>\n                    To investigate the effects of the second generation antipsychotic (R\/S)\u2010amisulpride, and the chirally purified enantiomers, on glucose homeostasis in diet\u2010induced obese (DIO) mice.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:<\/jats:bold>\n                    Normal and DIO mice were treated with pharmacologically relevant doses of amisulpride prior to oral glucose tolerance tests (OGTTs). Blood glucose, insulin, glucagon\u2010like peptide\u20101, prolactin and amisulpride drug levels were determined.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:<\/jats:bold>\n                    Racemic amisulpride significantly reduced glucose excursions during OGTT in both normal and DIO mice. This potent effect was preserved with the \u2018off\u2010isomer\u2019, R\u2010amisulpride (ED\n                    <jats:sub>50<\/jats:sub>\n                    1 mg\/kg). Insulin secretion was significantly increased with R\u2010amisulpride with only a minor increase in prolactin levels.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    Amisulpride has antidiabetic actions in DIO mice resulting from increased insulin secretion. This provides some explanation for why amisulpride, unlike other atypical antipsychotics, is not diabetogenic in man. Furthermore, the observation that R\u2010amisulpride is also antidiabetic and has minimal impact on prolactin levels presents the opportunity for development of this isomer as an antidiabetic agent.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2011.01529.x","type":"journal-article","created":{"date-parts":[[2011,11,7]],"date-time":"2011-11-07T13:14:35Z","timestamp":1320671675000},"page":"329-334","source":"Crossref","is-referenced-by-count":10,"title":["Effect of the antipsychotic agent amisulpride on glucose lowering and insulin secretion"],"prefix":"10.1111","volume":"14","author":[{"given":"J. J.","family":"Roix","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. A.","family":"DeCrescenzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. H.","family":"Cheung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. R.","family":"Ciallella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Sulpice","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Saha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Halse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,27]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(02)00588-7"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2007.01.003"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01416.x"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1463-1326.2005.00495.x"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0028-1100425"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-200418130-00007"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1177\/0269881106069467"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0b013e3181bf613e"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(02)01990-8"},{"key":"e_1_2_7_11_2","first-page":"419","article-title":"Hyperprolactinemia after low dose of amisulpride.","volume":"25","author":"Kopecek M","year":"2004","journal-title":"Neuro Endocrinol Lett"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S6226"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-2999(01)01484-4"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.2183\/pjab.86.563"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2782"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.76.s5.05"},{"key":"e_1_2_7_17_2","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0022-3565(24)36395-5","article-title":"Neurochemical characteristics of amisulpride, an atypical dopamine D2\/D3 receptor antagonist with both presynaptic and limbic selectivity.","volume":"280","author":"Schoemaker H","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-009-1521-8"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0064"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0024-3205(97)00599-7"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2010.01.029"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1210\/en.2009-0996"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e3280148c29"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-010-0277-9"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-009-0183-1"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2011.01529.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2011.01529.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:39:51Z","timestamp":1761867591000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2011.01529.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,27]]},"references-count":24,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["10.1111\/j.1463-1326.2011.01529.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2011.01529.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"value":"1462-8902","type":"print"},{"value":"1463-1326","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,27]]}}}